Healthcare Quality, Safety and Infection Control: Industry Report

Summary

Health care-associated infection (HAI) and other preventable harms are a persistent quality and safety problem. The World Health Organization states that the true global burden of HAI is unknown because surveillance is weak, and that the burden is several fold higher in low- and middle-income countries ¹. In the United States, surveillance data from the Centers for Disease Control and Prevention (CDC) and its National Healthcare Safety Network (NHSN) show declines in several device-associated and hospital-onset infections in the latest comparison period ⁴. Evidence on adverse events is consistent: about one in four hospitalized patients in a US study experienced at least one adverse event ⁸. The main risks are measurement gaps, inconsistent definitions across sources, and limited verified data on workforce, market value, reimbursement and digital adoption. The outlook favors continued surveillance-led improvement, with the largest uncertainty in low-resource settings where data are weakest.

Key findings

1. 1

   The global HAI burden is not reliably measured

   WHO describes HAI as infection acquired during care and not present at admission, and states that the true global burden remains unknown because surveillance is weak ¹. Any global prevalence figure should therefore be treated as incomplete.

   Confidence: High
2. 2

   Several US hospital infection measures fell in the latest comparison

   Reporting on CDC NHSN data describes a 9 percent fall in central line-associated bloodstream infections, a 10 percent fall in catheter-associated urinary tract infections, an 11 percent fall in hospital-onset C. difficile infections and a 7 percent fall in MRSA bacteremia at US acute care hospitals ⁴. This is secondary reporting, so the primary CDC report should be checked before use in formal decisions.

   Confidence: Medium
3. 3

   Infection prevalence is high among adult intensive care patients

   A peer-reviewed systematic review pooled bloodstream infection prevalence in adult ICU patients at 34.0 percent (95% confidence interval 25.0 to 42.0 percent), and urinary tract and surgical site infection prevalence at 26.0 percent (95% confidence interval 17.0 to 35.0 percent) ⁹. Study periods and settings were not stated in the source summary.

   Confidence: Medium
4. 4

   Adverse events are common and linked to higher mortality

   Almost 25 percent of patients in a US study experienced at least one adverse event during hospitalization, with adverse drug events, surgical or procedural events and HAIs as the most common types ⁸. A peer-reviewed review reports that patients with at least one adverse event are twice as likely to die during hospitalization ¹⁰.

   Confidence: Medium
5. 5

   The burden is largest in low- and middle-income countries and data are thin

   WHO/Europe reports an estimated 134 million adverse events a year in hospitals in low- and middle-income countries, with 2.6 million deaths ⁷. The pack does not verify current national data on water, sanitation and hygiene access, infection prevention staffing or costs in these settings, so this finding is directional rather than precise.

   Confidence: Qualitative

1Industry definition and scope

This report covers the quality, safety and infection control function within hospitals and other care facilities. It focuses on preventing and measuring harm that patients acquire during care, with HAI as the central category. WHO defines a health care-associated infection as an infection acquired during care in a facility that was not present at admission ¹.

The scope includes surveillance, prevention practice, patient safety measurement and the evidence used to judge performance. It also covers the broader class of avoidable harms that WHO lists, including medication errors, unsafe surgery, HAI, falls, pressure ulcers and venous thromboembolism ⁶. Infection control is treated as one part of this wider safety system.

Geography is global, with US and EU national data used where noted. The US figures come mainly from CDC surveillance and survey programs ⁵. The reporting period is the latest available data in the sources reviewed. Because the sources use different definitions, sample frames and periods, comparisons across them are indicative only.

Key terms: HAI refers to infection acquired in care. Device-associated measures include central line-associated bloodstream infection (CLABSI) and catheter-associated urinary tract infection (CAUTI). Hospital-onset C. difficile and MRSA bacteremia are also tracked ⁵. Adverse event is used in the wider sense of harm from care, which is broader than infection alone ⁸.

Scope is defined from the sources in the pack. No market boundaries or industry revenue definitions are verified.

2Market size, structure and value chain

The pack does not contain verified market size, spending, price or vendor revenue data for infection prevention and control products or services. This gap is material. No market value, growth rate or share figure is reported here.

Structurally, the system has three linked layers. Care providers deliver services and carry the risk of harm. Surveillance agencies collect and publish data, such as CDC through NHSN, which tracks HAIs across 25,000 US healthcare facilities ². Standards and research bodies, including WHO and peer-reviewed authors, define measures and evidence. Suppliers of products and services are not described in the pack, so supplier structure cannot be mapped.

The surveillance network is the most clearly documented part of the chain. CDC reports HAI data from two systems: NHSN and the Emerging Infections Program HAIC interface ⁵. The annual HAI Progress Report covers CLABSI, CAUTI, selected surgical site infections, hospital-onset C. difficile and MRSA bacteremia reported to NHSN ⁵. These reports are the basis for performance comparison across facilities.

Revenue models in the pack are not described. Public surveillance is funded and reported by government bodies, and the pack gives no information on how provider quality activity is paid for. Interpretation: the value chain is driven by measurement and reporting obligations, but the economic flows cannot be quantified from the sources provided.

• US healthcare facilities tracked by NHSN 25,000healthcare facilities Observed US, Latest available data [2]

Structure is described from surveillance and reporting evidence only; market value is explicitly not available.

3Customers, demand and adoption

The main end users are patients, who bear the harm, and health systems, which must reduce it. Demand for quality and infection control services follows the burden of infection. WHO notes that HAI is several fold higher in low- and middle-income countries than in high-income countries ¹, which indicates large unmet need in lower-resource settings.

The scale of the problem in intensive care is substantial. A systematic review reports pooled bloodstream infection prevalence of 34.0 percent and urinary tract or surgical site infection prevalence of 26.0 percent among adult ICU patients ⁹. These estimates are from pooled studies, so they describe the evidence base rather than a single population.

US survey data show the infection profile in hospitals. In a 10-state survey of 13,653 patients across 218 hospitals, pneumonia, surgical site and gastrointestinal infections were the most common HAIs, and 61 percent were not associated with devices or procedures ³. This matters for demand because non-device infections need broader practice measures than device bundles.

Reported figures show one in 38 hospital patients had at least one HAI on a given day in the latest survey, compared with one in 31 in an earlier period ². A separate CDC estimate cited in secondary coverage gives roughly one in 31 ⁴. The sources do not state matching periods, so the two figures cannot be reconciled and should not be combined.

Purchasing criteria and provider choice are not documented in the pack. No verified data on patient or payer preferences, adoption of quality programs or the effect of public reporting on choice are available. These are gaps for any commercial or policy assessment.

• Hospital patients with at least one HAI on a given day 1 in 38patients Observed US, 10 states, Latest available survey [2]
• Patients surveyed across participating hospitals 13,653patients Observed US, 10 states, Latest available survey [3]

Demand is inferred from burden and measured prevalence. Purchasing behavior and willingness to pay are not verified.

4Competitive landscape and key players

The pack does not name commercial vendors, product suppliers or private providers that compete in infection control or quality services. Comparable company examples are therefore limited, and this section cannot rank firms or compare market shares.

The named actors in the sources are public and academic bodies. CDC operates NHSN and the Emerging Infections Program, which provide surveillance data and reports ²⁵. WHO publishes global burden and patient safety guidance ¹⁶. WHO/Europe publishes adverse event estimates for low- and middle-income countries ⁷. These are reference bodies rather than competing providers, and their roles differ in purpose and scope.

A fair comparison of public, private and community providers is not possible from the pack. The sources do not give HAI or quality outcomes by provider type, so no public versus private versus community comparison is made. This is a material gap for any assessment of provider performance.

Concentration and competitive pressure cannot be assessed from the evidence. The main competitive pressure described in the sources is reputational and regulatory, linked to published surveillance results ²⁴. This is an interpretation, not a verified finding about market behavior.

Business model differences are also not supported by the pack. Providers that run surveillance programs differ from those that only report data, but the pack gives no verified detail on how these models compare in cost or outcomes.

No vendor or provider comparison is made because comparable data are not in the pack.

5Technology, operations and workforce

Infection surveillance relies on structured reporting systems. NHSN is the main US system for HAI tracking ²⁵, and the Emerging Infections Program supports population-based survey methods ³⁵. These systems are established practice, and their data underpin the national trends reported.

Operational practice is shown by the measures that changed. Device-associated infections, such as CLABSI and CAUTI, fell in the latest comparison, along with hospital-onset C. difficile and MRSA bacteremia ⁴. The pack does not link these changes to specific interventions, so causal claims about practice are not supported.

Emerging or experimental approaches, such as new digital surveillance tools or automated detection, are not described with verified adoption rates in the pack. The adoption of digital health or surveillance technology for infection prevention is therefore a data gap. Any claim about the productivity effect of such tools would be interpretation.

Workforce capacity is a major gap. The pack contains no verified data on infection prevention staffing, staffing ratios or shortages. Without these figures, the link between staffing and infection outcomes cannot be quantified from the sources, and this report does not estimate it.

Established practice is distinguished from emerging approaches on the basis of sources named in the pack. No adoption rate data are used.

6Regulation, standards, risk and sustainability

The pack does not contain verified regulatory text, binding rules or payment policies for either the United States or the European Union. Regulatory requirements are therefore not described in detail. Readers should check the primary legal sources in their jurisdiction before relying on any compliance point.

In the US, surveillance is conducted through CDC programs, and performance is reported through the annual HAI Progress Report ⁵. Whether specific reporting is mandatory or voluntary is not verified in the pack. The pack also does not verify US hospital-acquired condition payment rules, so reimbursement effects cannot be assessed.

WHO sets the global framing for patient safety and HAI measurement ¹⁶. Its guidance is an international reference, not a binding national law in most settings. EU-level rules for infection control are not verified in the pack, so no EU binding requirement is stated.

Risk is clearest in measurement. WHO notes that weak surveillance limits knowledge of the true burden ¹. Differences in definitions and periods across sources, such as the two competing one-in-31 and one-in-38 figures, add risk of misreading trends ²⁴. Operational risk also includes avoidable harms that WHO lists as common ⁶.

Environmental and social factors are referenced only in part. WHO/Europe notes that a share of hospital activity and expenditure in OECD countries results from adverse events, estimated at 15 percent ⁷. This is an estimate with an unstated period, and it is not a direct measure of environmental impact. Water, sanitation and hygiene access in low-resource settings is described only qualitatively in the pack.

No legal conclusions are drawn. This section is general industry analysis, not legal or regulatory advice.

7Challenges, opportunities and case examples

The main constraint is weak measurement. WHO states that the true global burden remains unknown ¹. Without stronger surveillance, providers and policymakers cannot target the largest gaps, especially in low-income settings where the burden is several fold higher ¹.

Harm is also expensive. WHO/Europe estimates that adverse events account for 15 percent of hospital activity and expenditure in OECD countries ⁷. Adverse events are also associated with higher mortality risk ¹⁰. This creates a strong case for prevention, although the pack does not quantify the return on prevention spending.

Opportunities follow from the measured declines. CDC-reported reductions in device-associated and hospital-onset infections show that targeted measures can move reported rates ⁴. Broader application of the same measurement approach, and extension of surveillance beyond the US, are logical next steps, but the pack does not verify their cost or effect.

Case example 1: CDC's NHSN and its annual HAI Progress Report. NHSN tracks HAIs across 25,000 US facilities ², and the report covers CLABSI, CAUTI, selected surgical site infections, hospital-onset C. difficile and MRSA bacteremia ⁵. It shows how a national reporting system supports trend monitoring.

Case example 2: CDC's Emerging Infections Program survey. The survey covered 13,653 patients in 218 hospitals across 10 states and found that 61 percent of HAIs were not associated with devices or procedures ³. It shows the value of survey data for capturing infections that device-based surveillance would miss. Comparable company examples were limited in the pack, so both examples are public agency programs.

The chart shows reported changes only. Causes of the declines are not established in the pack.

8Outlook and strategic implications

In the near term, the most evidence-based expectation is continued reliance on national surveillance to track HAI trends. CDC reporting shows declines across several measures ⁴, and the NHSN base of 25,000 facilities provides a platform for continued monitoring ². This is an interpretation of current reporting, not a forecast from the pack.

In the medium term, the largest uncertainty is whether the gains extend to non-device infections, which made up 61 percent of HAIs in the survey ³, and to low-resource settings where surveillance is weakest ¹. Progress in these areas is not verified in the pack.

Practical implications differ by stakeholder. Hospitals should focus on the infection types most common in the latest survey and on ICU populations with high reported prevalence ³⁹. Policymakers should prioritize better surveillance in low- and middle-income countries ¹⁷. Suppliers and digital health firms would need verified adoption and cost data before making claims about market opportunity, which the pack does not supply.

No quantitative forecast is presented because no verified forecast is in the pack.

9Conclusion

Infection and adverse events remain common in care, and their true global burden is poorly measured. The most defensible takeaways are that US surveillance shows declines in several hospital infection measures, that ICU patients carry high reported infection prevalence, and that data gaps on workforce, costs and reimbursement limit confident judgments on the market.

How this was built

Sources

1. 1

   The burden of health care-associated infection worldwide

   World Health Organization Official statistics

   who.int
2. 2

   CDC survey data show decline in healthcare-associated infections at US hospitals

   CIDRAP (reporting on CDC and state health department survey data) News report

   cidrap.umn.edu
3. 3

   New CDC Data Shows Decline in Healthcare-Associated Infections

   Centers for Disease Control and Prevention Official statistics

4. 4

   CDC data show decline in hospital-related infections

   CIDRAP (reporting on CDC NHSN data) News report

5. 5

   HAIs: Reports and Data

   Centers for Disease Control and Prevention Official statistics

   cdc.gov
6. 6

   Patient safety

   World Health Organization Official statistics

   who.int
7. 7

   Patient Safety - Key facts

   WHO/Europe Official statistics

   who-dev5.prgsdev.com
8. 8

   Almost 1 in 4 patients experienced an adverse event while hospitalized

   Advisory Board (reporting on a New England Journal of Medicine study) News report

9. 9

   Prevalence of Healthcare-Acquired Infections Among Adults in Intensive Care Units: A Systematic Review and Meta-Analysis

   Peer-reviewed systematic review (journal authors not captured in result) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
10. 10

    Adverse events: an expensive and avoidable hospital problem

    Peer-reviewed study (authors not captured in result) Peer-reviewed

    pmc.ncbi.nlm.nih.gov